| Title: | Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease |
| Journal: | Nature Medicine |
| Published: | 7 Nov 2019 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/31700174/ |
| DOI: | https://doi.org/10.1038/s41591-019-0627-8 |
| URL: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858876 |
| Citations: | 193 (84 in last 2 years) as of 8 Aug 2024 |
Publication 3639
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Chronic kidney disease is common in the general population and associated with excess cardiovascular disease (CVD), but kidney function does not feature in current CVD risk-prediction models. We tested three formulae for estimated glomerular filtration rate (eGFR) to determine which was the most clinically informative for predicting CVD and mortality. Using data from 440,526 participants from UK Biobank, eGFR was calculated using serum creatinine, cystatin C (eGFRcys) and creatinine-cystatin C. Associations of each eGFR with CVD outcome and mortality were compared using Cox models and adjusting for atherosclerotic risk factors (per relevant risk scores), and the predictive utility was determined by the C-statistic and categorical net reclassification index. We show that eGFRcys is most strongly associated with CVD and mortality, and, along with albuminuria, adds predictive discrimination to current CVD risk scores, whilst traditional creatinine-based measures are weakly associated with risk. Clinicians should consider measuring eGFRcys as part of cardiovascular risk assessment.</p>
14 Authors
- Jennifer S. Lees
- Claire E. Welsh
- Carlos A. Celis-Morales
- Daniel Mackay
- James Lewsey
- Stuart R. Gray
- Donald M. Lyall
- John G. Cleland
- Jason M. R. Gill
- Pardeep S. Jhund
- Jill Pell
- Naveed Sattar
- Paul Welsh
- Patrick B. Mark
1 Application
| Application ID | Title |
|---|---|
| 9310 | Associations of blood biomarkers with cardiovascular disease and related cardiometabolic outcomes and risk prediction in the clinical setting |
Enabling scientific discoveries that improve human health